36 results about "Immune monitoring" patented technology

The invention relates to a method for quantitatively identifying relevant HLA-bound peptide antigens from primary tissue specimens on a large scale without labeling approaches. This method can not only be used for the development of peptide vaccines, but is also highly valuable for a molecularly defined immunomonitoring and the identification of new antigens for any immunotherapeutic strategy in which HLA-restricted antigenic determinants function as targets, such as a variety of subunit vaccines or adoptive T-cell transfer approaches in cancer, or infectious and autoimmune diseases.

It is intended to provide a convenient immunity monitoring system whereby T cell frequencies specific to a plural number of antigen peptides can be assayed by using a relatively small amount of blood. Peripheral monocytes are collected and frequently stimulated with an antigen without directly using any antigen presenting cells. Then T cells specific to the antigen in the thus stimulated peripheral monocytes are detected to thereby detect antigen-specific T cells. thus, diseases such as cancer can be prevented or treated with the use of a peptide having such a function, in particular, cancer tumor-rejection antigen peptide.

The invention discloses a selenium cyclic peptide and fatty acid mixture which is prepared from the traditional Chinese medicines of ginseng, radix rubiae, fructus lycii, fructus schisandrae chinensis, semen coicis, poria cocos, radix pseudostellariae, fructus gardeniae, selenium and the like by the modern microbial fermentation technology. The histone deacetylase all-natural synergic combined inhibitor with a brand-new chemical structure comprises the combined compounds such as selenium peptide, cyclic peptide, short-chain fatty acid and the like, and belongs to the tumor epigenetic regulation medicine of a novel anti-tumor action mechanism; and different from the traditional tumor treatment medicine, the selenium cyclic peptide and fatty acid mixture disclosed by the invention performs saturation attack by taking the abnormal epigenetic inheritance of tumor cells as a target spot, exerts an overall synergic anti-tumor effect by inducing the immunologic surveillance and immunity killing function of a patient, and is anti-oxidant and all-natural without chemical pollution.

The invention provides a preparation method of an anti-neweastle disease virus specific transfer factor. The method comprises the following steps: selecting a healthy chicken as an experiment chicken to carry out supplementary immunization of a newcastle disease inactivated vaccine; monitoring the level of an immune antibody of the newcastle disease vaccine inside the experiment chicken body; taking splenic organs of the experiment chicken in a sterile condition when the level of the antibody achieves 28-29; and processing the splenic organs of the chicken, so as to obtain the anti-neweastle disease virus specific transfer factor. By adopting the anti-neweastle disease virus specific transfer factor disclosed by the invention, the specific immune effect of the chicken body on a neweastle disease virus antigen can be improved; normal cells of the body can be prevented from being infected by the virus. Thus, the transfer factor disclosed by the invention can play the roles in preventing the neweastle disease virus infection and protecting normal cells of the body from being damaged by the neweastle disease virus, so as to reduce the morbidity; meanwhile, the chicken infected by the neweastle disease virus can be treated by using the transfer factor. Therefore, the clinical symptoms can be effectively improved; the recovery rate is increased; the mortality is reduced.

The invention discloses a method for detecting bastard halibut LITAF gene expression by applying reverse transcription-polymerase chain reaction (RT-PCR). The method lays a foundation for studying bastard halibut LITAF gene expression regulation mechanism and immunology function. TNF-alpha plays an important role in the process of immune response and foreign pathogenic bacteria killing, and the LITAF is a transcription factor of TNF-alpha gene and directly controls the expression of the TNF-alpha gene. Therefore, the expression abundance of the LITAF gene reflects the activity of a bastard halibut immune system to a certain extent and can be used as an immune monitoring index and immune agent quality evaluation index in prevention and treatment of bastard halibut diseases. By detecting the variation of the bastard halibut LITAF gene expression quantity, whether the bastard halibut is infected with a disease can be judged in advance and a measure of prevention and treatment can be taken timely so as to avoid unavoidable loss resulting from serious situation; and besides, the advantages and disadvantages of a fish immune agent can be evaluated so as to judge which immune agent has better effect during prevention and treatment of flounder diseases. The invention provides a technology platform for relative quantitative analysis of LITAF gene at the mRNA level.

The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and / or autoimmune diseases.

The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and / or autoimmune diseases.

The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

The invention discloses a class of interferon gene stimulating factor (STING) targeting imaging agent, which is based on the structure of benzothiophene and composed of radionuclide 18 F marker, which can be used for PET imaging of interferon gene stimulators, its general structural formula is shown in formula A, where n=1‑5: formula A where the benzothiophene structure is used as a targeting group, and polyethylene glycol alcohol as a hydrophilic group, 18 F is a radioactive group. The molecular targeting imaging agent has excellent targeting and specificity to interferon gene stimulators, and can be used for PET imaging to monitor inflammation and immune responses produced by tumors. The molecule can specifically distinguish immune responses of different severities, and meets the conditions of being used as an imaging agent for immune monitoring.